Tecentriq (atezolizumab)

Atirizumab, duvalizumab, atezolizumab, and serplulimab can significantly improve the clinical outcomes of SCLC. Finally, we clarified that the emerging trend of low-dose radiotherapy help overcome the inhibitory signals that limit T-cell infiltration in the tumor matrix. In summary, considering the rapid development of this field, these combined therapy strategies may have unlimited potential to further improve the efficacy of radiotherapy combined with immunotherapy for patients.

P2, N=80, Active, not recruiting, AIO-Studien-gGmbH | Recruiting --> Active, not recruiting | Trial completion date: Nov 2026 --> Apr 2027 | Trial primary completion date: Nov 2026 --> Apr 2027

P1/2, N=48, Recruiting, University Health Network, Toronto | Not yet recruiting --> Recruiting

P2, N=3, Active, not recruiting, Liza Villaruz, MD | Recruiting --> Active, not recruiting | N=35 --> 3 | Trial completion date: Apr 2029 --> Aug 2026 | Trial primary completion date: Sep 2027 --> Aug 2024

P2, N=40, Recruiting, ImmunityBio, Inc. | Active, not recruiting --> Recruiting | N=147 --> 40

P3, N=100, Completed, Roche Farma S.A.

P1/2, N=518, Recruiting, Hoffmann-La Roche | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Dec 2026

P3, N=238, Recruiting, Gruppo Oncologico del Nord-Ovest

P3, N=49, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | N=100 --> 49

P2, N=20, Not yet recruiting, Emory University

P2, N=106, Completed, Vanderbilt-Ingram Cancer Center | Active, not recruiting --> Completed

These findings suggest that the mGPS measured at the time of radiologic PD can identify patients with a better prognosis who may benefit from continued atezolizumab therapy, aiding in the selection for TBP in clinical practice.

P2/3, N=542, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: May 2027 --> Dec 2025

P2, N=26, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 --> Oct 2026

P2, N=175, Active, not recruiting, German Cancer Research Center | Recruiting --> Active, not recruiting

P3, N=517, Active, not recruiting, UNICANCER | Trial primary completion date: Oct 2024 --> Jun 2025

P1/2, N=48, Not yet recruiting, University Health Network, Toronto

P2, N=20, Recruiting, University Medical Center Groningen | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2024 --> Apr 2025

Serum IL-6 levels are thought to be involved in the suppression of tumor immunity and are useful in predicting the therapeutic effect of Atezo+Bev treatment.

P1, N=498, Recruiting, Genentech, Inc. | Trial completion date: Nov 2024 --> Mar 2026 | Trial primary completion date: Nov 2024 --> Mar 2025

Our work revealed iRT was prolonged OS in previously treated advanced NSCLC patients. Additionally, proliferative CD4+ T cell served as prognostic and predictive biomarkers.

P2, N=24, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting

P2, N=240, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

P3, N=829, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Oct 2024 --> Aug 2025

P1, N=54, Not yet recruiting, EMD Serono Research & Development Institute, Inc.

Consistent with preclinical results, inhibition of A2ARs using ciforadenant in combination with programmed death 1 ligand 1 (PD-L1) blockade using atezolizumab induces clinical responses in patients with mCRPC. Moreover, inhibiting A2ARs results in a significant decrease in SPP1hi-TAM abundance in CRPC, indicating that this pathway is involved in both induction and downstream immunosuppression. Collectively, these findings establish SPP1hi-TAMs as key mediators of ICI resistance in mCRPC through adenosine signalling, emphasizing their importance as both a therapeutic target and a potential biomarker for predicting treatment efficacy.

P1, N=518, Completed, Genentech, Inc. | Active, not recruiting --> Completed

Five months after, the patient complained of abdominal pain, with an alpha-fetoprotein (AFP) level exceeding 9000 ng/ml, and CT images showed liver metastases and multiple lung metastases, so treatment with immunotherapy atezolizumab plus bevacizumab was started in September 2022. However, abdominal pain improved, and AFP decrease, raising suspicion of pseudoprogression. Treatment was therefore continued until radiological progression could be confirmed with a follow-up CT scan after 2 months, which revealed a complete response of the pulmonary metastasis and a partial response of the liver metastasis.

P=N/A, N=111, Not yet recruiting, Oncology Center of Biochemical Education And Research

P2, N=46, Active, not recruiting, Deepak Kilari | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Jun 2025

P1/2, N=89, Completed, Syndax Pharmaceuticals | Phase classification: P1b --> P1/2

Patients who tested positive for IC had a significantly longer PFS than those who tested negative. Thus, PD-L1 expression may be a predictive factor of efficacy of chemoimmunotherapy in extensive-stage small cell lung cancer.

Following production in a 7-L bioreactor, atezolizumab was purified using a three-step chromatographic method. Finally, the purified atezolizumab was characterized and compared with commercial atezolizumab (Tecentriq) through several chromatographic and kinetics analyses.

P2, N=115, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris

P1, N=26, Completed, Nykode Therapeutics ASA | Active, not recruiting --> Completed | N=60 --> 26

Especially, RNA-seq analysis and Western blotting further revealed that CXCL9/10-CXCR3 axis was markedly up-regulated and JAK/STAT1 pathway was activated upon treatment with PPAB001 plus Tecentriq. Overall, our results underscore that simultaneous blockade of CD47 and CD24 is a potential therapeutic option to improve the efficacy of anti-PD-L1 therapy mainly by resetting tumor-associated macrophages toward M1 phenotype.

P3, N=439, Not yet recruiting, BioNTech SE

These results revealed that in FAT1-L AML cells, inhibiting autophagy by CQ enhances the cytotoxic effect of IDA, but leads to immune escape, resulting in AML recurrence. Our study supports the use of a combination of autophagy and PD-L1 inhibitors with IDA to increase the cytotoxic effect of IDA while inhibiting AML recurrence.

LIPI was prognostic for PFS and OS in prospective trials in aNSCLC, regardless of the treatment regimen. LIPI poor patients derived no benefit from combination treatment. LIPI combined to PD-L1 may improve the upfront treatment selection.

The ATEZO DHT NP could specifically target to tumor and enhance treatment efficiency through combination of PD-L1 blockade with ICD effect.

P2, N=63, Recruiting, Samsung Medical Center | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Sep 2023 --> Nov 2025

P1, N=120, Active, not recruiting, InxMed (Shanghai) Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025